- PTAB upheld key claims in U.S. Patent No. 11,435,360 covering Proteograph nanoparticle protein-enrichment methods in a challenge brought by Bruker subsidiaries PreOmics GmbH and Biognosys AG.
- Final Written Decision dated March 23, 2026 left 23 claims valid, including five of 11 challenged claims.
- Patent is owned by Brigham and Women’s Hospital and exclusively licensed to Seer.
- Ruling preserves intellectual property protection for Proteograph-based deep proteomic analysis across multiple biological sample types.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Seer Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202603300700PRIMZONEFULLFEED9680486) on March 30, 2026, and is solely responsible for the information contained therein.
Comments